RxDoctor Payments Data

Bishnu Sapkota, MD

Neurology · Granbury, TXNPI 1679702872

Payments from drug & device makers

$34,254in general payments, 2019–2025

Across 2,069 payments — averaging $16.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • UCB, Inc.$3K
  • E.r. Squibb & Sons, L.L.C.$3K
  • Biogen$2K
  • Novartis$1K
  • Teva Pharmaceuticals USA, Inc.$1K
  • plus $19K from 54 others

What the payments were for

  • Consulting fees$2,8008%
  • Travel & lodging$1,6325%
  • Food & beverage$29,50586%
  • Education$3171%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)376$4,402
UCB, Inc.187$3,151
E.r. Squibb & Sons, L.L.C.5$2,993
Biogen108$1,746
Novartis99$1,402
Teva Pharmaceuticals USA, Inc.86$1,224
Pfizer105$1,178
Bristol Myers Squibb13$1,081
Amgen(2 entities)81$1,005
Medtronic16$998
Neurelis, Inc.53$995
Lilly USA, LLC60$879
Upsher-smith Laboratories LLC62$757
Lundbeck LLC50$721
Amneal Pharmaceuticals LLC50$712
Acadia Pharmaceuticals Inc45$683
Genentech USA, Inc.39$669
Argenx US, Inc.44$627
Sanofi38$626
Supernus Pharmaceuticals, Inc.42$518
Biohaven Pharmaceuticals, Inc.82$483
Livanova USA, Inc.9$438
Grifols USA, LLC21$404
Aucta Pharmaceuticals, Inc.24$403
SK Life Science, Inc.25$393
Eisai Inc.24$357
Otsuka America Pharmaceutical, Inc.18$351
Biohaven Pharmaceutical Holding Company Ltd.28$313
Jazz Pharmaceuticals Inc.13$305
Adamas Pharmaceuticals, Inc.20$299
Impel Pharmaceuticals Inc.25$293
MDD US Operations, LLC9$257
Avanir Pharmaceuticals, Inc.19$253
Sumitomo Pharma America, Inc.13$248
AstraZeneca14$234
Vanda Pharmaceuticals Inc.13$210
CSL Behring11$177
Greenwich Biosciences, Inc.9$173
Neurocrine Biosciences, Inc.10$167
Kyowa Kirin, Inc.8$160
TG Therapeutics, Inc.8$158
Currax Pharmaceuticals LLC17$148
Arbor Pharmaceuticals, Inc.10$125
Ipsen Biopharmaceuticals, Inc6$114
Revance Therapeutics, Inc.2$104
Alnylam Pharmaceuticals Inc.5$102
Avion Pharmaceuticals6$100
Johnson & Johnson4$92
EMD Serono, Inc.5$89
Aquestive Therapeutics, Inc.6$86
Amylyx Pharmaceuticals, Inc.4$77
Nevro Corp.4$75
Cycle Pharmaceuticals Inc3$73
Tanabe Pharma America, Inc.4$71
Almatica Pharma LLC3$59
Averitas Pharma Inc.2$57
Saol Therapeutics Inc.1$55
Azurity Pharmaceuticals, Inc.3$40
Promius Pharma LLC3$40
ANI Pharmaceuticals, Inc.2$32

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$34,254 in reported general payments places this provider in the 80th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas

Medicare billing

Part B allowed, 2024
$274,655
Medicare patients
832
Services billed
6,584

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SolirisEculizumab18$895,186
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5052$369,432
FinteplaFenfluramine Hcl13$265,248
AustedoDeutetrabenazine12$204,531
Kesimpta PenOfatumumab20$199,315
IngrezzaValbenazine Tosylate18$155,483
NuplazidPimavanserin Tartrate28$139,517
EpidiolexCannabidiol (Cbd)21$139,121
AptiomEslicarbazepine Acetate53$66,437
Gamunex-CImmune Globul G/Gly/Iga Avg 4613$54,851
GocovriAmantadine Hcl13$47,422
AmpyraDalfampridine11$46,826
VimpatLacosamide32$41,796
BriviactBrivaracetam25$38,857
QuliptaAtogepant34$38,020

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaSoliris$234$895,18618 claims
CSL BehringPrivigen$177$369,43252 claims
UCB, Inc.Fintepla, Vimpat, Briviact$3,151$345,90170 claims
Teva Pharmaceuticals USA, Inc.Austedo$1,224$204,53112 claims
Neurocrine Biosciences, Inc.Ingrezza$167$155,48318 claims
Acadia Pharmaceuticals IncNuplazid$683$139,51728 claims
AbbVieQulipta, Ubrelvy, Botox$4,402$93,27779 claims
Grifols USA, LLCGamunex-C$404$54,85113 claims
MDD US Operations, LLCGocovri$257$47,42213 claims
Neurelis, Inc.Valtoco$995$37,38512 claims
Eisai Inc.Banzel$357$27,80612 claims
PfizerNurtec Odt$1,178$19,53218 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,246 neurology providers in Texas.

Other neurology in Granbury

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →